1. Clinical & Scientific Overview
Risperidone & Olanzapine (TIP-MED-000456, Reference Code [11.24]) is classified under
CNS & Psychiatric Medicines as a Second-Generation (Atypical) Serotonin-Dopamine (5-HT2A/D2) Antagonist Antipsychotics (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 (Rx — 3-Year Register Retention & Red-Border Warning).
Representative Indian Formulations (for identification only): Risperidone: Sizodon (Sun), Risdone (Intas), Risperdal (J&J), Respidon (Torrent). Olanzapine: Oleanz (Sun), Oliza (Intas), Olimelt (MD), Zyprexa; | Strengths: Risperidone Tablets / MD: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg; Oral Solution: 1 mg/mL; Long-Acting Depot Injection: 25/37.5/50 mg q2w. Olanzapine Tablets / Mouth-Dissolving (MD): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg; IM Injection: 10 mg
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Second-Generation (Atypical) Serotonin-Dopamine (5-HT2A/D2) Antagonist Antipsychotics (Schedule H | NLEM 2022)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Schizophrenia and other psychotic disorders, acute manic or mixed episodes in Bipolar I Disorder, treatment-resistant depression (Olanzapine + Fluoxetine), and severe refractory aggression/psychosis in autism or dementia (short-term <=6 weeks at 0.
4. Therapeutic Indications & Evidence-Supported Uses
- Schizophrenia and other psychotic disorders, acute manic or mixed episodes in Bipolar I Disorder, treatment-resistant depression (Olanzapine + Fluoxetine), and severe refractory aggression/psychosis in autism or dementia (short-term <=6 weeks at 0
- 25–0
- 5 mg only when non-pharmacological measures fail!)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Risperidone (Schizophrenia/Mania): Start 1–2 mg/day PO (OD or BD), titrate to target **2–4 mg/day** (Doses >6 mg/day cause high EPS without added efficacy!; in Elderly/CKD/Hepatic: Start 0.25–0.5 mg BD!). (Duration: Long-term relapse prevention in schizophrenia/bipolar disorder; taper gradually when discontinuing)
Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified) | Food & Meal Timing: May be taken with or without food; Mouth-Dissolving (MD) tablets dissolve on tongue in seconds (useful in acute psychiatric agitation/non-adherence) | Best Time of Day: Bedtime (HS — leverages sedation for sleep and reduces daytime orthostasis) or BD (Risperidone)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal & Hepatic: Risperidone active metabolite (9-OH-risperidone / Paliperidone) is renally cleared -> halve Risperidone starting and maintenance doses (0.5 mg BD) if CrCl <30 mL/min or in cirrhosis! Olanzapine: Start at 2.5–5 mg OD in hepatic impairment
Renal & Hepatic: Risperidone active metabolite (9-OH-risperidone / Paliperidone) is renally cleared -> halve Risperidone starting and maintenance doses (0.5 mg BD) if CrCl <30 mL/min or in cirrhosis! Olanzapine: Start at 2.5–5 mg OD in hepatic impairment
Renal & Hepatic: Risperidone active metabolite (9-OH-risperidone / Paliperidone) is renally cleared -> halve Risperidone starting and maintenance doses (0.5 mg BD) if CrCl <30 mL/min or in cirrhosis! Olanzapine: Start at 2.5–5 mg OD in hepatic impairment
7. Contraindications, Precautions & High-Risk Warnings
- BOXED WARNING — INCREASED MORTALITY & CEREBROVASCULAR STROKE IN ELDERLY DEMENTIA PATIENTS: All atypical and typical antipsychotics increase all-cause mortality (1
- 6–1
- 7x, primarily from pneumonia, heart failure, & sudden cardiac death) and stroke/TIA in elderly patients with dementia-related psychosis! Contraindicated in coma/severe CNS d
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Risperidone (High D2 & Alpha-1 affinity): Dose-dependent **Hyperprolactinaemia** (highest among atypicals along with Amisulpride/Paliperidone -> galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction, osteoporosis!), dose-dependent EPS/akathisia (at >4
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Risperidone: CYP2D6 inhibitors (Fluoxetine, Paroxetine, Bupropion, Terbinafine) increase active moiety levels
- Carbamazepine/Phenytoin reduce Risperidone levels by 50%
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- FOUR VITAL COUNTER RULES: (1) Avoid standalone Sizodon Plus / Risdone Plus (fixed-dose Risperidone + Trihexyphenidyl) in older patients or long-term unless EPS is actually present
- (2) On Oleanz/Oliza, weigh yourself weekly, watch for increased thirst/urination (high blood sugar), and exercise/limit sweets from Day 1
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Risperidone Tablets / MD: 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg; Oral Solution: 1 mg/mL; Long-Acting Depot Injection: 25/37.5/50 mg q2w. Olanzapine Tablets / Mouth-Dissolving (MD): 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg; IM Injection: 10 mg). Missed-Dose Rule: Take at bedtime as soon as remembered; never double dose or stop suddenly
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)